For example, overtreatment may result when care providers offer risk-reducing mastectomy (RRM) to female RPPV carriers with or without a BC diagnosis, even though their risks may be similar to carriers of PVs in moderate penetrance genes such as ATM or CHEK2 for which RRM is not recommended68. The gene discussed is CHEK2; the disease is breast cancer.